


RealRate

PHARMACEUTICAL 2017

EMERGENT

Emergent BioSolutions Inc. Rank 31 of 313





PHARMACEUTICAL 2017





Emergent BioSolutions Inc. Rank 31 of 313

The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 350% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 545% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	510,218
Cost of Goods Sold	0
Intangible Assets	74,866
Liabilities, Current	105,856
Liabilities, Non-Current	249,698
Other Assets	8,579
Other Compr. Net Income	-1,618
Other Expenses	167,981
Other Liabilities	18,352
Other Net Income	-17,049
Property and Equipment	376,448
Research and Development	108,290
Revenues	488,782
Selling, General and Administrative Expense	143,686

Output Variable	Value in 1000 USD
Assets	970,111
Liabilities	373,906
Expenses	419,957
Stockholders Equity	596,205
Net Income	51,776
Comprehensive Net Income	50,967
Economic Capital Ratio	128%